Ying Shen

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

Wanhong Zhao, Jie Liu, Baiyan Wang et al. · Journal of Hematology & Oncology · 2018 · 526 citations · Full text

Immunology, Immunodominance, Immunotherapeutics +19

Time course of femoral neck osteopenia in ovariectomized rats

M. Li, Ying Shen, Thomas J. Wronski · Bone · 1997 · 103 citations

Bone Remodeling, Osteoarthritis, Time Course +4

Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Baiyan Wang, Wanhong Zhao, Jie Liu et al. · Blood · 2019 · 91 citations

Circ-ANAPC7 is Upregulated in Acute Myeloid Leukemia and Appears to Target the MiR-181 Family

Hongli Chen, Tian Liu, Jing Liu et al. · Cellular Physiology and Biochemistry · 2018 · 89 citations · Full text

Iron metabolism gene expression and prognostic features of hepatocellular carcinoma

Ying Shen, Xin Li, Bin Zhao et al. · Journal of Cellular Biochemistry · 2018 · 84 citations